Straticyte™ Presented at the 7th World Congress of the International Academy of Oral Oncology

MaRS Discovery District, Toronto, ON; September 4, 2019 – Proteocyte AI, a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON, announces today that an abstract and poster titled “Clinical Management of Patients with Oral Epithelial Dysplasia and Elevated Straticyte™ Risk for Progression to Cancer” was presented at the 7th World Congress of the International Academy of Oral Oncology.

Dr. Barrie Renick, Proteocyte Advisor, was in attendance and presented a clinical case of a tongue lesion using both the standard assessment by an oral pathologist and a novel risk assessment by Straticyte. Straticyte identified this lesion as high-risk of progression to cancer while H&E only showed mild dysplasia/minimal risk. This lesions went on to develop oral cancer in 30 months. Dr. Renick says: “the ability of Straticyte to identify subcellular changes in the tissue, before any microscopic changes are seen, is potentially ground-breaking. I was excited to share my findings in Rome at the World Congress among such esteemed colleagues. The work of Proteocyte is experiencing global recognition and Straticyte was discussed in some detail in a lecture by Dr. Moni Kuriakose of India. His lecture addressed the need for reliable biomarkers in oral cancer prevention and presents an opportunity for tests like Straticyte in India, a country where over a quarter of the world’s mouth cancers occur annually.”

The 7th World Congress of the International Academy of Oral Oncology: Joining efforts for improved outcomes and quality of care, overseen by the Academy’s current President and Toronto’s own Dr. Ralph Gilbert, was held in Rome, Italy on August 31 – September 3, 2019. It is a global summit that convenes every two years and is attended by the most prominent Head & Neck Surgeons, Otorhinolaryngologists, Radiation and Medical Oncologists, Maxillofacial Surgeons and all other allied specialists in Oral Cancer. This year’s attendance and presenters included renowned experts Drs. Pat Gullane and Jatin Shah, as well as Proteocyte Advisor Dr. Ian Witterick.

About Proteocyte

Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D and is positioned to disrupt oral dysplasia and cancer care worldwide.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.